FIELD: organic chemistry; pharmaceuticals.
SUBSTANCE: invention relates to a new compound used for the treatment of cancer associated with the expression of CXCR4. The compound of the invention is 8-(4-hydroxy-2-methoxyphenoxy)-6-methoxy-3-pentylquinoline-2,4(1H,3H)-dione (keto tautomer) or 4-hydroxy-8-(4-hydroxy-2-methoxyphenoxy)-6-methoxy-3-pentylquinolin-2(1H)-one (enol tautomer).
EFFECT: obtaining of 8-(4-hydroxy-2-methoxyphenoxy)-6-methoxy-3-pentylquinoline-2,4(1H,3H)-dione or 4-hydroxy-8-(4-hydroxy-2-methoxyphenoxy)-6-methoxy-3-pentylquinolin-2(1H)-one for the treatment of cancer associated with CXCR4 expression.
8 cl, 35 dwg, 6 ex
Title | Year | Author | Number |
---|---|---|---|
SDF-1 BINDING NUCLEIC ACIDS AND USE THEREOF | 2008 |
|
RU2612388C2 |
SMALL MOLECULES FOR INHIBITING CHEMOKINE ACTIVITY AND/OR MALIGNANT TUMOR CELL GROWTH | 2016 |
|
RU2773652C2 |
SDF1-BINDING NUCLEIC ACIDS AND USE THEREOF IN CANCER TREATMENT | 2011 |
|
RU2679495C2 |
I-3859 ANTIBODY APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636032C2 |
HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
SDF-1 BINDING NUCLEIC ACIDS | 2007 |
|
RU2590709C2 |
NEW ANTIBODY TO CXCR4 AND ITS APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636345C2 |
CANCER MARKER AND THERAPEUTIC TARGET | 2008 |
|
RU2529797C2 |
ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
POLYPEPTIDES FOR TREATMENT OF DISEASES | 2018 |
|
RU2792848C2 |
Authors
Dates
2024-03-06—Published
2020-05-15—Filed